PDE5A and chronic obstructive pulmonary disease: Several clinical studies have demonstrated that drugs with vasodilatory effects, such as phosphodiesterase 5 (PDE-5) inhibitors and ACEIs, could increase PMBF and delay COPD progression, suggesting the therapeutic potential of vasodilators for early-stage COPD.[11,12]